ROP logo

Roche Holding AG Stock Price

SWX:ROP Community·CHF 253.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

ROP Share Price Performance

CHF 317.20
62.40 (24.49%)
CHF 352.00
Fair Value
CHF 317.20
62.40 (24.49%)
9.9% undervalued intrinsic discount
CHF 352.00
Fair Value
Price CHF 317.20
AnalystConsensusTarget CHF 352.00
AnalystLowTarget CHF 295.00
AnalystHighTarget CHF 428.00

ROP Community Narratives

AnalystConsensusTarget·
Fair Value CHF 352 9.9% undervalued intrinsic discount

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystLowTarget·
Fair Value CHF 295 7.5% overvalued intrinsic discount

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value CHF 428 25.9% undervalued intrinsic discount

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CHF 428
25.9% undervalued intrinsic discount
Revenue
4.11% p.a.
Profit Margin
27.22%
Future PE
19.58x
Price in 2029
CHF 480.25
CHF 352
9.9% undervalued intrinsic discount
Revenue
2.1% p.a.
Profit Margin
25.47%
Future PE
18.25x
Price in 2029
CHF 394.97
CHF 295
7.5% overvalued intrinsic discount
Revenue
-0.18% p.a.
Profit Margin
25.03%
Future PE
16.65x
Price in 2029
CHF 331.01

Trending Discussion

Updated Narratives

ROP logo

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Fair Value: CHF 428 25.9% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ROP logo

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Fair Value: CHF 352 9.9% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ROP logo

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Fair Value: CHF 295 7.5% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with solid track record and pays a dividend.

1 Risk
5 Rewards

Roche Holding AG Key Details

CHF 63.4b

Revenue

CHF 16.2b

Cost of Revenue

CHF 47.2b

Gross Profit

CHF 34.3b

Other Expenses

CHF 12.9b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 23, 2026
16.19
74.49%
20.33%
83.5%
View Full Analysis

About ROP

Founded
1896
Employees
103249
CEO
Thomas Schinecker
WebsiteView website
www.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.

Recent ROP News & Updates

Recent updates

No updates